Virginie Durbecq

4.2k total citations · 1 hit paper
64 papers, 3.1k citations indexed

About

Virginie Durbecq is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Virginie Durbecq has authored 64 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 25 papers in Molecular Biology and 23 papers in Cancer Research. Recurrent topics in Virginie Durbecq's work include HER2/EGFR in Cancer Research (19 papers), Breast Cancer Treatment Studies (17 papers) and Cancer Treatment and Pharmacology (10 papers). Virginie Durbecq is often cited by papers focused on HER2/EGFR in Cancer Research (19 papers), Breast Cancer Treatment Studies (17 papers) and Cancer Treatment and Pharmacology (10 papers). Virginie Durbecq collaborates with scholars based in Belgium, United Kingdom and Italy. Virginie Durbecq's co-authors include Christos Sotiriou, Denis Larsimont, Fátima Cardoso, Marianne Paesmans, Martine Piccart, Max S. Mano, Evandro de Azambuja, M. Piccart-Gebhart, Gilberto de Castro and Angelo Di Leo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Virginie Durbecq

64 papers receiving 3.0k citations

Hit Papers

Ki-67 as prognostic marke... 2007 2026 2013 2019 2007 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
    2007 724 citations Evandro de Azambuja, Fátima Cardoso et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Virginie Durbecq Belgium 29 1.8k 1.5k 1.3k 454 433 64 3.1k
Thomas Karn Germany 37 2.2k 1.2× 1.7k 1.1× 2.3k 1.8× 691 1.5× 392 0.9× 141 4.9k
Timothy E. Kute United States 33 2.0k 1.1× 1.3k 0.9× 1.8k 1.3× 369 0.8× 500 1.2× 78 4.2k
Giulia Viale Italy 26 1.9k 1.1× 1.3k 0.8× 814 0.6× 660 1.5× 365 0.8× 69 3.2k
Junichi Kurebayashi Japan 37 1.9k 1.1× 999 0.7× 1.8k 1.4× 425 0.9× 273 0.6× 157 3.8k
Mohammed A. Aleskandarany United Kingdom 36 1.6k 0.9× 1.5k 1.0× 1.7k 1.3× 510 1.1× 382 0.9× 81 3.4k
Ludmila Prudkin United States 23 1.9k 1.1× 1.5k 1.0× 1.7k 1.3× 804 1.8× 537 1.2× 50 3.8k
Petra van der Groep Netherlands 33 1.2k 0.7× 1.7k 1.1× 1.9k 1.5× 488 1.1× 261 0.6× 67 3.7k
I E Smith United Kingdom 23 1.8k 1.0× 1.5k 1.0× 777 0.6× 657 1.4× 457 1.1× 59 3.5k
Theodoros Foukakis Sweden 33 2.1k 1.2× 1.5k 1.0× 1.4k 1.1× 726 1.6× 299 0.7× 135 4.1k
Jaime Mejia United States 13 2.4k 1.4× 2.0k 1.3× 1.2k 0.9× 649 1.4× 501 1.2× 45 3.8k

Countries citing papers authored by Virginie Durbecq

Since Specialization
Citations

This map shows the geographic impact of Virginie Durbecq's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virginie Durbecq with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virginie Durbecq more than expected).

Fields of papers citing papers by Virginie Durbecq

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virginie Durbecq. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virginie Durbecq. The network helps show where Virginie Durbecq may publish in the future.

Co-authorship network of co-authors of Virginie Durbecq

This figure shows the co-authorship network connecting the top 25 collaborators of Virginie Durbecq. A scholar is included among the top collaborators of Virginie Durbecq based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virginie Durbecq. Virginie Durbecq is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ignatiadis, Michail, Françoise Rothé, Carole Chaboteaux, et al.. (2011). HER2-Positive Circulating Tumor Cells in Breast Cancer. PLoS ONE. 6(1). e15624–e15624. 159 indexed citations
2.
Desmedt, Christine, Jeff Sperinde, Fanny Piette, et al.. (2009). Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH. Diagnostic Molecular Pathology. 18(1). 22–29. 31 indexed citations
3.
Ma, Xiaojun, Ranelle Salunga, Sonika Dahiya, et al.. (2008). A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clinical Cancer Research. 14(9). 2601–2608. 227 indexed citations
4.
Galmarini, Carlos M., Isabelle Treilleux, Fátima Cardoso, et al.. (2008). Class III β-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel. Clinical Cancer Research. 14(14). 4511–4516. 55 indexed citations
5.
Durbecq, Virginie, Lieveke Ameye, Isabelle Veys, et al.. (2008). A significant proportion of elderly patients develop hormone-dependant “luminal-B” tumours associated with aggressive characteristics. Critical Reviews in Oncology/Hematology. 67(1). 80–92. 44 indexed citations
6.
Larsimont, Denis, Virginie Durbecq, Ahmad Awada, & Angelo Di Leo. (2008). [HER2 and topoisomerase II alpha: useful clinical markers in breast cancer].. PubMed. 95(3). 344–51. 2 indexed citations
7.
Azambuja, Evandro de, Virginie Durbecq, Daniela Dornelles Rosa, et al.. (2007). HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Annals of Oncology. 19(2). 223–232. 32 indexed citations
8.
Durbecq, Virginie & Fátima Cardoso. (2007). Topoisomerase-II as a predictive marker for response to anthracyclines. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 2(4). 49–57. 1 indexed citations
9.
Leo, Angelo Di, Minna Tanner, Christine Desmedt, et al.. (2007). p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Annals of Oncology. 18(6). 997–1003. 49 indexed citations
10.
Lago, Lissandra Dal, Virginie Durbecq, Christine Desmedt, et al.. (2006). Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Molecular Cancer Therapeutics. 5(10). 2572–2579. 59 indexed citations
11.
Cardoso, Fátima, Virginie Durbecq, Jean‐François Laes, et al.. (2006). Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner. Molecular Cancer Therapeutics. 5(12). 3042–3051. 49 indexed citations
12.
Sotiriou, Christos, Pratyaksha Wirapati, Sherene Loi, et al.. (2005). Better characterization of estrogen receptor (ER) positive luminal subtypes using genomic grade. Breast Cancer Research and Treatment. 94. 7 indexed citations
13.
Desmedt, Christine, Sherene Loi, Benjamin Haibe‐Kains, et al.. (2005). Four genes by RT-PCR predicts distant relapse for women given adjuvant tamoxifen. Breast Cancer Research and Treatment. 94. 133. 2 indexed citations
14.
Leo, Angelo Di, Stephen Chan, Marianne Paesmans, et al.. (2004). HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel. Breast Cancer Research and Treatment. 86(3). 197–206. 121 indexed citations
15.
Mano, Max S., Ahmad Awada, Angelo Di Leo, et al.. (2004). Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gynecologic Oncology. 92(3). 887–895. 42 indexed citations
16.
Desmedt, Christine, Minna Tanner, Angelo Di Leo, et al.. (2004). p-53 gene mutations as a predictive marker in advanced breast cancer patients randomly treated either with doxorubicin or with docetaxel. Breast Cancer Research and Treatment. 2 indexed citations
17.
Desmedt, Christine, Denis Larsimont, Marianne Paesmans, et al.. (2004). Molecular classification of breast carcinomas by immunohistochemistry (IHC) using the tissue microarrays (TMA): new subtypes with clinical relevance?. Breast Cancer Research and Treatment. 88. 1 indexed citations
18.
Desmedt, Christine, Virginie Durbecq, Marianne Paesmans, et al.. (2004). Topoisomerase II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated with single-agent doxorubicin or single-agent docetaxel. Cancer Research. 64. 263–263. 40 indexed citations
19.
Massant, Jan, Patrik Verstreken, Virginie Durbecq, et al.. (2002). Metabolic Channeling of Carbamoyl Phosphate, a Thermolabile Intermediate. Journal of Biological Chemistry. 277(21). 18517–18522. 17 indexed citations
20.
Marina, Alberto, Santiago Ramón‐Maiques, Vicente Rubio, et al.. (2001). [21] Carbamoyl phosphate synthesis: Carbamate kinase from Pyrococcus furiosus. Methods in enzymology on CD-ROM/Methods in enzymology. 331. 236–247. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Karn Breakdown of academic impact, for papers by Timothy E. Kute Breakdown of academic impact, for papers by Giulia Viale Breakdown of academic impact, for papers by Junichi Kurebayashi Breakdown of academic impact, for papers by Mohammed A. Aleskandarany Breakdown of academic impact, for papers by Ludmila Prudkin Breakdown of academic impact, for papers by Petra van der Groep Breakdown of academic impact, for papers by I E Smith Breakdown of academic impact, for papers by Theodoros Foukakis Breakdown of academic impact, for papers by Jaime Mejia
Rankless by CCL
2026